



PRESS RELEASE

REGULATED INFORMATION

5 March 2020, 07:00 CET

Biocartis Creates New Share Option Plan & Cancels Outstanding Pool under 2018 Share Option Plan

Mechelen, Belgium, 5 March 2020 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that its board of directors created, within the framework of the authorized capital, 696,976 share options (each share option having the form of a subscription right) under a new share option plan, called the 'Share Option Plan 2020', in order to enable the Company to offer the share options to certain personnel members of the Company and/or its subsidiaries.

The share options under the Share Option Plan 2020 have a term of ten years (unless contractually reduced in the offer to a beneficiary), are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of share options is made to a beneficiary. Each share option gives the right to subscribe to one new ordinary Biocartis share. The exercise price of a share option will be determined by the board of directors of the Company when offering the share option to a beneficiary and will at least be equal to the average closing price of the shares of the Company on Euronext Brussels during the thirty day period prior to the date of the offer. Should the share options be exercised, Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The share option as such will not be listed on any stock market.

The purpose of the Share Option Plan 2020 is to create a plan of subscription rights for shares of the Company in accordance with the provisions of the (new) Belgian Code of Companies and Associations ('BCCA') consisting of a number of share options that is the same as the number of share options which have not yet been offered to, and accepted by, the beneficiaries under the '2018 Share Option Plan' which was created on 10 September 2018 in accordance with the provisions of the Belgian Companies Code of 7 May 1999. Consequently, the Company canceled an equal number of outstanding share options under the Company's 2018 Share Option Plan that have not yet been offered to, and accepted by, the beneficiaries of the 2018 Share Option Plan. Hence, the total number of outstanding share options has not increased.

The reports prepared by the board of directors and the Company's statutory auditor (in accordance with Article 7:198 *juncto* Articles 7:180 and 7:191 of the BCCA) in the framework of the creation of the Share Option Plan 2020 can be consulted on the website of the [Company](#).

----- END -----

More information:

Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64

[@Biocartis](#) www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on [Twitter](#): @Biocartis.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.